4-phenylbutyl nitrate | 130209-92-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-phenylbutyl nitrate
• 英文别名: 4-Phenyl-1-butylnitrat；3-phenylbutyl nitrate；4-phenyl-1-butanol nitrate
• CAS: 130209-92-6
• 化学式: C₁₀H₁₃NO₃
• 分子量: 195.218
• InChiKey: RIENQZNVXGBCRD-UHFFFAOYSA-N

物化性质

• 沸点：
  298.2±19.0 °C(Predicted)
• 密度：
  1.119±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-phenylbutyl nitrate 在 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以97 %的产率得到4-phenyl-1-iodobutane
  参考文献：
  名称：

  10.1002/anie.202411073

  摘要：

  Nitrate esters hold pivotal roles in pharmaceuticals, energetic materials, and atmospheric processes, motivating the development of efficient synthesis routes. Here, we present a novel catalytic method for the synthesis of nitrates via the direct O‐nitration of alcohols, addressing limitations of current traditional methods. Leveraging bench‐stable and recoverable N,6‐dinitrosaccharin reagent, our catalytic strategy employs magnesium triflate to achieve mild and selective O‐nitration of alcohols, offering broad substrate scope and unprecedented large functional group tolerance (e.g. alkenes, alkynes, carbonyls). DFT mechanistic studies reveal a dual role of the magnesium catalyst in the activation of both the nitrating reagent and the alcohol substrate. They also unveil a barrierless proton transfer upon formation of a widely‐accepted — yet elusive in solution — nitrooxonium ion intermediate. Overall, our work contributes to the development of mild, selective, and sustainable approaches to nitrates synthesis, with potential applications in drug discovery, materials science, and environmental chemistry.

  DOI：

  10.1002/anie.202411073
• 作为产物：
  描述：

  4-苯基丁醇 生成 4-phenylbutyl nitrate
  参考文献：
  名称：

  Pharmaceutical composition having relaxing activity which contains a

  摘要：

  该发明涉及含有新型硝酸酯的药物组合物，发现它们对治疗缺血性心脏病、心力衰竭、心肌梗死和高血压有用。

  公开号：

  US05049694A1

文献信息

• Anti-Markovnikov hydrochlorination and hydronitrooxylation of α-olefins via visible-light photocatalysis
  作者：Jungwon Kim、Xiang Sun、Boris Alexander van der Worp、Tobias Ritter

  DOI：10.1038/s41929-023-00914-7

  日期：——

  that utilize radical intermediates have been demonstrated, but only for activated alkenes, and the direct use of aqueous mineral acids remains elusive. Here we present anti-Markovnikov addition reactions of aqueous hydrochloric and nitric acid to unactivated alkenes. The transformation is enabled by the in situ generation of photoredox-active ion pairs, derived from acridine and the mineral acid, as

  α-烯烃与无机酸的常规加氢官能化以 Markovnikov 选择性进行，以提供支化异构体。线性结构异构体的直接形成具有挑战性，但反马尔可夫尼科夫加成对合成商品化学品很有价值，例如伯醇，目前只能通过化学计量氧化还原反应获得，完全等量地浪费氧化剂和还原剂。利用自由基中间体的策略已经得到证明，但仅适用于活化的烯烃，直接使用无机酸水溶液仍然难以捉摸。在这里，我们介绍了盐酸和硝酸水溶液与未活化烯烃的反马尔可夫尼科夫加成反应。这种转化是通过原位产生光氧化还原活性离子对实现的，衍生自吖啶和无机酸，作为电荷转移和相转移的组合催化剂。氢原子转移催化剂的引入使我们能够绕过源自高键离解能的盐酸和硝酸具有挑战性的链增长。
• Pharmaceutical composition having relaxing activity which contains a nitrate ester as active substance
  申请人：CEDONA PHARMACEUTICALS B.V.

  公开号：EP0359335A2

  公开（公告）日：1990-03-21

  The invention relates to pharmaceutical compositions containing novel nitrate esters, of which it was found that they are useful for the treatment of ischemiatic heart diseases, decompensatio cordis, myocardial infarct­ion, hypertension, etc., said novel nitrate esters meet formula 1 as defined in claim 1.

  本发明涉及含有新型硝酸酯的药物组合物，发现这些药物组合物可用于治疗异质性心脏病、心肌缺血、心肌梗塞、高血压等，所述新型硝酸酯符合权利要求1中定义的式1。
• [DE] VERWENDUNG VON SUBSTITUIERTEN ALKYLNITRATEN ZUR BEHANDLUNG DES KRANKHAFT ERHÖHTEN AUGENINNENDRUCKES<br/>[EN] USE OF SUBSTITUTED ALKYL NITRATES FOR THE TREATMENT OF PATHOLOGICALLY INCREASED INTRA-OCULAR PRESSURE<br/>[FR] UTILISATION DE NITRATES D'ALKYLE SUBSTITUES POUR LE TRAITEMENT D'UN ACCROISSEMENT PATHOLOGIQUE DE LA PRESSION INTRA-OCULAIRE
  申请人：BYK NEDERLAND BV

  公开号：WO1994021248A1

  公开（公告）日：1994-09-29

  (DE) Die Erfindung betrifft die Verwendung von Verbindungen der Formel (I), worin R1 und R2 die in der Beschreibung angegebenen Bedeutungen haben, und ihren pharmakologisch verträglichen Salzen zur Herstellung von Arzneimitteln für die Behandlung des krankhaft erhöhten Augeninnendruckes.(EN) The invention pertains to the use of compounds of formula (I) wherein R1 and R2 stand for the constituents indicated in the description, and of their pharmacologically tolerable salts in the preparation of medicines for the treatment of pathologically increased intra-ocular pressure.(FR) L'invention concerne l'utilisation de composés de formule (I), dans laquelle R1 et R2 ont les notations données dans la description, et de leurs sels pharmacologiquement tolérables pour la fabrication de médicaments destinés au traitement d'un accroissement pathologique de la pression intra-oculaire.

  该发明涉及使用形式为(I)的化合物及其 pharmakologically tolerable 盐，以制备用于治疗视力增高的药物。
• VERWENDUNG VON SUBSTITUIERTEN ALKYLNITRATEN ZUR BEHANDLUNG DES KRANKHAFT ERHÖHTEN AUGENINNENDRUCKES
  申请人：BYK NEDERLAND BV

  公开号：EP0689435A1

  公开（公告）日：1996-01-03
• Methods and means for preventing or treating inflammation or pruritis
  申请人：——

  公开号：US20040166183A1

  公开（公告）日：2004-08-26

  The invention relates to methods and means for preventing, treating or reducing inflammation by inhibiting proteolytic activity, more specifically for preventing or reducing inflammations of skin or intestine. The invention provides a method for reducing or preventing an inflammation comprising subjecting a mammal to a treatment with at least one inhibitor which is capable of inhibiting proteolytic activity. In a preferred embodiment of the invention, said inhibitor is a plant product, such as potato juice or an inhibitor derived thereof.